Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Analysts

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Hold” from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $11.10.

Several analysts have commented on the stock. Barclays restated an “equal weight” rating and set a $8.00 price objective on shares of Certara in a research note on Friday, March 6th. Morgan Stanley reduced their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. KeyCorp decreased their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Leerink Partners reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Certara in a report on Thursday, February 26th. Finally, Stephens cut their price target on Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th.

Certara Stock Down 1.6%

Certara stock opened at $5.41 on Friday. The business’s 50-day simple moving average is $7.02 and its two-hundred day simple moving average is $9.16. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. The company has a market cap of $860.95 million, a PE ratio of -541.00 and a beta of 1.62. Certara has a fifty-two week low of $5.24 and a fifty-two week high of $15.38.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities analysts anticipate that Certara will post 0.28 EPS for the current year.

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its holdings in Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after acquiring an additional 4,244,230 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Certara during the 4th quarter worth approximately $26,706,000. Deerfield Management Company L.P. increased its holdings in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after purchasing an additional 2,813,438 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Certara by 1,430.6% in the 2nd quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock valued at $17,694,000 after purchasing an additional 1,413,538 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Certara by 133.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after purchasing an additional 1,299,109 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.